Search: id:"swepub:oai:lup.lub.lu.se:8f70b87b-ca2d-46aa-97e4-eb75ef53fadf" >
Donanemab in Early ...
Donanemab in Early Symptomatic Alzheimer Disease : The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
-
- Sims, John R. (author)
- Eli Lilly and Company
-
- Zimmer, Jennifer A. (author)
- Eli Lilly and Company
-
- Evans, Cynthia D. (author)
- Eli Lilly and Company
-
show more...
-
- Lu, Ming (author)
- Eli Lilly and Company
-
- Ardayfio, Paul (author)
- Eli Lilly and Company
-
- Sparks, Jon David (author)
- Eli Lilly and Company
-
- Wessels, Alette M. (author)
- Eli Lilly and Company
-
- Shcherbinin, Sergey (author)
- Eli Lilly and Company
-
- Wang, Hong (author)
- Eli Lilly and Company
-
- Monkul Nery, Emel Serap (author)
- Eli Lilly and Company
-
- Collins, Emily C. (author)
- Eli Lilly and Company
-
- Solomon, Paul (author)
- Boston University
-
- Salloway, Stephen (author)
- Brown University
-
- Apostolova, Liana G. (author)
- Indiana University
-
- Hansson, Oskar (author)
- Lund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,LU profilområde: Proaktivt åldrande,Lunds universitets profilområden,Clinical Memory Research,Lund University Research Groups,LU Profile Area: Proactive Ageing,Lund University Profile areas,Skåne University Hospital
-
Ritchie, Craig (author)
-
- Brooks, Dawn A. (author)
- Eli Lilly and Company
-
- Mintun, Mark (author)
- Eli Lilly and Company
-
- Skovronsky, Daniel M. (author)
- Eli Lilly and Company
-
show less...
-
(creator_code:org_t)
- 2023
- 2023
- English 16 s.
-
In: JAMA. - 0098-7484. ; 330:6, s. 512-527
- Related links:
-
http://dx.doi.org/10...
-
show more...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Importance: There are limited efficacious treatments for Alzheimer disease. Objective: To assess efficacy and adverse events of donanemab, an antibody designed to clear brain amyloid plaque. Design, Setting, and Participants: Multicenter (277 medical research centers/hospitals in 8 countries), randomized, double-blind, placebo-controlled, 18-month phase 3 trial that enrolled 1736 participants with early symptomatic Alzheimer disease (mild cognitive impairment/mild dementia) with amyloid and low/medium or high tau pathology based on positron emission tomography imaging from June 2020 to November 2021 (last patient visit for primary outcome in April 2023). Interventions: Participants were randomized in a 1:1 ratio to receive donanemab (n = 860) or placebo (n = 876) intravenously every 4 weeks for 72 weeks. Participants in the donanemab group were switched to receive placebo in a blinded manner if dose completion criteria were met. Main Outcomes and Measures: The primary outcome was change in integrated Alzheimer Disease Rating Scale (iADRS) score from baseline to 76 weeks (range, 0-144; lower scores indicate greater impairment). There were 24 gated outcomes (primary, secondary, and exploratory), including the secondary outcome of change in the sum of boxes of the Clinical Dementia Rating Scale (CDR-SB) score (range, 0-18; higher scores indicate greater impairment). Statistical testing allocated α of.04 to testing low/medium tau population outcomes, with the remainder (.01) for combined population outcomes. Results: Among 1736 randomized participants (mean age, 73.0 years; 996 [57.4%] women; 1182 [68.1%] with low/medium tau pathology and 552 [31.8%] with high tau pathology), 1320 (76%) completed the trial. Of the 24 gated outcomes, 23 were statistically significant. The least-squares mean (LSM) change in iADRS score at 76 weeks was -6.02 (95% CI, -7.01 to -5.03) in the donanemab group and -9.27 (95% CI, -10.23 to -8.31) in the placebo group (difference, 3.25 [95% CI, 1.88-4.62]; P <.001) in the low/medium tau population and -10.2 (95% CI, -11.22 to -9.16) with donanemab and -13.1 (95% CI, -14.10 to -12.13) with placebo (difference, 2.92 [95% CI, 1.51-4.33]; P <.001) in the combined population. LSM change in CDR-SB score at 76 weeks was 1.20 (95% CI, 1.00-1.41) with donanemab and 1.88 (95% CI, 1.68-2.08) with placebo (difference, -0.67 [95% CI, -0.95 to -0.40]; P <.001) in the low/medium tau population and 1.72 (95% CI, 1.53-1.91) with donanemab and 2.42 (95% CI, 2.24-2.60) with placebo (difference, -0.7 [95% CI, -0.95 to -0.45]; P <.001) in the combined population. Amyloid-related imaging abnormalities of edema or effusion occurred in 205 participants (24.0%; 52 symptomatic) in the donanemab group and 18 (2.1%; 0 symptomatic during study) in the placebo group and infusion-related reactions occurred in 74 participants (8.7%) with donanemab and 4 (0.5%) with placebo. Three deaths in the donanemab group and 1 in the placebo group were considered treatment related. Conclusions and Relevance: Among participants with early symptomatic Alzheimer disease and amyloid and tau pathology, donanemab significantly slowed clinical progression at 76 weeks in those with low/medium tau and in the combined low/medium and high tau pathology population. Trial Registration: ClinicalTrials.gov Identifier: NCT04437511.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
-
JAMA
(Search for host publication in LIBRIS)
To the university's database
- By the author/editor
-
Sims, John R.
-
Zimmer, Jennifer ...
-
Evans, Cynthia D ...
-
Lu, Ming
-
Ardayfio, Paul
-
Sparks, Jon Davi ...
-
show more...
-
Wessels, Alette ...
-
Shcherbinin, Ser ...
-
Wang, Hong
-
Monkul Nery, Eme ...
-
Collins, Emily C ...
-
Solomon, Paul
-
Salloway, Stephe ...
-
Apostolova, Lian ...
-
Hansson, Oskar
-
Ritchie, Craig
-
Brooks, Dawn A.
-
Mintun, Mark
-
Skovronsky, Dani ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Neurology
- Articles in the publication
-
JAMA
- By the university
-
Lund University